Rigel (RIGL) Surges 19.7%: Is This an Indication of Further Gains? [Yahoo! Finance]
Rigel Pharmaceuticals, Inc. (RIGL)
Last rigel pharmaceuticals, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.rigel.com
Company Research
Source: Yahoo! Finance
The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 1.6% gain over the past four weeks. Earlier this month, the company enrolled the first patient in a phase Ib/II triplet therapy study, which evaluated its marketed drug Rezlidhia (olutasidenib) in combination with decitabine and venetoclax for the treatment of mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML). This might have driven the share price rally. This drug developer is expected to post quarterly earnings of $0.01 per share in its upcoming report, which represents a year-over-year change of +103.3%. Revenues are expected to be $40.69 million, up 44.7% from the year-ago quarter. Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price moveme
Show less
Read more
Impact Snapshot
Event Time:
RIGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RIGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RIGL alerts
High impacting Rigel Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RIGL
News
- Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its price target raised by analysts at Cantor Fitzgerald from $15.00 to $25.00. They now have a "neutral" rating on the stock.MarketBeat
- Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $57.00 price target on the stock.MarketBeat
- Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition [Yahoo! Finance]Yahoo! Finance
- Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and ExpositionPR Newswire
- Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its price target raised by analysts at B. Riley from $17.00 to $27.00. They now have a "neutral" rating on the stock.MarketBeat
RIGL
Earnings
- 11/7/24 - Beat
RIGL
Sec Filings
- 12/9/24 - Form 8-K
- 11/26/24 - Form 4
- 11/26/24 - Form 4
- RIGL's page on the SEC website